Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (Review).

Exp Ther Med

Division of Human Gene Therapy, Departments of Medicine, Pathology, Surgery, Obstetrics and Gynecology, The Gene Therapy Center, Birmingham, AL, USA.

Published: March 2010

The purpose of this article was to review the current strategies of targeted therapy to integrins and define the best course of future research in ovarian cancer targeting. Cell surface integrin targeting has been used as a strategy for targeted therapy of several diseases with some success. The combination of virotherapy and integrin-targeting shows promise as a method for targeting ovarian cancer. More specifically, targeting of ovarian cancer with integrin-directed adenoviruses may lead to therapy with fewer toxicities and side effects. This article offers a review of the benefits of integrin-specific targeted therapy for several diseases and proposes a unique anti-ovarian cancer strategy involving the combination of the above with virotherapy as a potential anti-ovarian cancer treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3008561PMC
http://dx.doi.org/10.3892/etm_00000037DOI Listing

Publication Analysis

Top Keywords

ovarian cancer
16
targeted therapy
12
cancer targeting
8
therapy diseases
8
combination virotherapy
8
targeting ovarian
8
anti-ovarian cancer
8
cancer
6
targeting
5
role rgd-containing
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!